R292K 取代与流感 A(H7N9)病毒的药物敏感性。
R292K substitution and drug susceptibility of influenza A(H7N9) viruses.
出版信息
Emerg Infect Dis. 2013;19(9):1521-4. doi: 10.3201/eid1909.130724.
Abstract
Neuraminidase inhibitors are the only licensed antiviral medications available to treat avian influenza A(H7N9) virus infections in humans. According to a neuraminidase inhibition assay, an R292K substitution reduced antiviral efficacy of inhibitors, especially oseltamivir, and decreased viral fitness in cell culture. Monitoring emergence of R292K-carrying viruses using a pH-modified neuraminidase inhibition assay should be considered.
摘要
神经氨酸酶抑制剂是目前唯一获准用于治疗人类感染甲型 H7N9 禽流感病毒的抗病毒药物。根据神经氨酸酶抑制试验，R292K 取代降低了抑制剂（特别是奥司他韦）的抗病毒功效，并降低了病毒在细胞培养中的适应性。应考虑使用 pH 改良的神经氨酸酶抑制试验监测携带 R292K 的病毒的出现。
相似文献
1
R292K substitution and drug susceptibility of influenza A(H7N9) viruses.R292K 取代与流感 A(H7N9)病毒的药物敏感性。
Emerg Infect Dis. 2013;19(9):1521-4. doi: 10.3201/eid1909.130724.
2
Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.人感染 H7N9 流感病毒分离株中 R292K 突变导致对神经氨酸酶抑制剂的耐药性可被混合的 R/K 病毒群所掩盖。
mBio. 2013 Jul 16;4(4):e00396-13. doi: 10.1128/mBio.00396-13.
3
Profile and generation of reduced neuraminidase inhibitor susceptibility in highly pathogenic avian influenza H7N9 virus from human cases in Mainland of China, 2016-2019.2016-2019 年中国大陆人感染高致病性禽流感 H7N9 病毒中神经氨酸酶抑制剂耐药性降低的特征和产生。
Virology. 2020 Oct;549:77-84. doi: 10.1016/j.virol.2020.07.018. Epub 2020 Aug 8.
4
Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.甲型H7N9流感病毒中赋予对奥司他韦耐药性的神经氨酸酶突变
J Virol. 2015 May;89(10):5419-26. doi: 10.1128/JVI.03513-14. Epub 2015 Mar 4.
5
[Drug susceptibility of wild-type and mutant H7N9 neuraminidase to zanamivir and oseltamivir].[野生型和突变型H7N9神经氨酸酶对扎那米韦和奥司他韦的药物敏感性]
Bing Du Xue Bao. 2014 Jul;30(4):396-401.
6
Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts.高致病性禽流感 H7N9 病毒对神经氨酸酶抑制剂的敏感性降低，其复制能力与敏感病毒相当。
Virol J. 2019 Jul 2;16(1):87. doi: 10.1186/s12985-019-1194-9.
7
Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.甲型流感病毒（H7N9）在不失体内毒力和传染性的情况下获得神经氨酸酶抑制剂耐药性。
Nat Commun. 2013;4:2854. doi: 10.1038/ncomms3854.
8
Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.神经氨酸酶抑制剂存在下连续传代选择的 A(H7N9) 流感病毒中神经氨酸酶的取代特征。
Antiviral Res. 2019 Aug;168:68-75. doi: 10.1016/j.antiviral.2019.05.009. Epub 2019 May 25.
9
Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.从台湾一名接受奥司他韦治疗的患者中分离出的耐药甲型H7N9流感病毒变异株的特征分析
J Infect Dis. 2015 Jan 15;211(2):249-57. doi: 10.1093/infdis/jiu447. Epub 2014 Aug 14.
10
Computational assay of H7N9 influenza neuraminidase reveals R292K mutation reduces drug binding affinity.计算分析 H7N9 流感神经氨酸酶表明 R292K 突变降低了药物结合亲和力。
Sci Rep. 2013 Dec 20;3:3561. doi: 10.1038/srep03561.
引用本文的文献
1
Influenza neuraminidase mutations and resistance to neuraminidase inhibitors.流感神经氨酸酶突变与对神经氨酸酶抑制剂的耐药性。
Emerg Microbes Infect. 2024 Dec;13(1):2429627. doi: 10.1080/22221751.2024.2429627. Epub 2024 Nov 26.
2
Genetic and virological characteristics of a reassortant avian influenza A H6N1 virus isolated from wild birds at a live-bird market in Egypt.从埃及活禽市场的野鸟中分离到的重组禽流感病毒 A(H6N1)的遗传和病毒学特征。
Arch Virol. 2024 Apr 9;169(5):95. doi: 10.1007/s00705-024-06022-6.
3
Highly Pathogenic Avian Influenza A(H5N1) Virus Clade 2.3.4.4b in Wild Birds and Live Bird Markets, Egypt.埃及野生鸟类和活禽市场中的高致病性甲型流感病毒（H5N1）2.3.4.4b分支毒株
Pathogens. 2022 Dec 26;12(1):36. doi: 10.3390/pathogens12010036.
4
Phylogeography and Biological Characterizations of H12 Influenza A Viruses.H12 型甲型流感病毒的系统地理学与生物学特性分析。
Viruses. 2022 Oct 13;14(10):2251. doi: 10.3390/v14102251.
5
Detection of a Novel Reassortant H9N9 Avian Influenza Virus in Free-Range Ducks in Bangladesh.孟加拉国散养鸭中新型 H9N9 禽流感病毒的检测。
Viruses. 2021 Nov 24;13(12):2357. doi: 10.3390/v13122357.
6
Functional neuraminidase inhibitor resistance motifs in avian influenza A(H5Nx) viruses.禽流感 A(H5Nx)病毒中的功能性神经氨酸酶抑制剂耐药性基序。
Antiviral Res. 2020 Oct;182:104886. doi: 10.1016/j.antiviral.2020.104886. Epub 2020 Aug 1.
7
H7N9 Influenza Virus in China.中国的 H7N9 流感病毒。
Cold Spring Harb Perspect Med. 2021 Aug 2;11(8):a038349. doi: 10.1101/cshperspect.a038349.
8
Antivirals Targeting the Neuraminidase.抗神经氨酸酶药物。
Cold Spring Harb Perspect Med. 2022 Jan 4;12(1):a038455. doi: 10.1101/cshperspect.a038455.
9
Inventory of molecular markers affecting biological characteristics of avian influenza A viruses.影响甲型禽流感病毒生物学特性的分子标志物清单。
Virus Genes. 2019 Dec;55(6):739-768. doi: 10.1007/s11262-019-01700-z. Epub 2019 Aug 19.
10
A Single Amino Acid Substitution at Residue 218 of Hemagglutinin Improves the Growth of Influenza A(H7N9) Candidate Vaccine Viruses.一个位于血凝素 218 位的氨基酸单点替换提高了流感 A(H7N9)候选疫苗病毒的生长能力。
J Virol. 2019 Sep 12;93(19). doi: 10.1128/JVI.00570-19. Print 2019 Oct 1.
本文引用的文献
1
Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.新型甲型 H7N9 流感病毒导致的人类疾病不良临床结局与病毒持续排出和抗病毒耐药性的出现之间的关联。
Lancet. 2013 Jun 29;381(9885):2273-9. doi: 10.1016/S0140-6736(13)61125-3. Epub 2013 May 29.
2
Emergence of avian influenza A(H7N9) virus causing severe human illness - China, February-April 2013.人感染 H7N9 禽流感疫情信息 - 中国，2013 年 2 月至 4 月
MMWR Morb Mortal Wkly Rep. 2013 May 10;62(18):366-71.
3
Human infection with a novel avian-origin influenza A (H7N9) virus.人感染新型甲型 H7N9 流感病毒。
N Engl J Med. 2013 May 16;368(20):1888-97. doi: 10.1056/NEJMoa1304459. Epub 2013 Apr 11.
4
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.2011 年南半球流感季节期间全球流行的流感病毒神经氨酸酶抑制剂敏感性监测。
Influenza Other Respir Viruses. 2013 Sep;7(5):645-58. doi: 10.1111/irv.12113. Epub 2013 Apr 10.
5
Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012.世界卫生组织流感抗病毒药物敏感性监测工作组会议——2011年11月于日内瓦及2012年6月于日内瓦
Wkly Epidemiol Rec. 2012 Sep 28;87(39):369-74.
6
Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.流感病毒中的神经氨酸酶抑制剂耐药性及实验室检测方法
Antivir Ther. 2012;17(1 Pt B):159-73. doi: 10.3851/IMP2067. Epub 2012 Feb 3.
7
Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model.评估使用竞争混合模型的抗奥司他韦流感病毒在雪貂中的病毒适应性。
J Virol. 2010 Sep;84(18):9427-38. doi: 10.1128/JVI.00373-10. Epub 2010 Jul 14.
8
Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses.焦磷酸测序作为检测季节性甲型流感病毒中神经氨酸酶抑制剂耐药分子标志物的工具。
Antiviral Res. 2009 Jan;81(1):16-24. doi: 10.1016/j.antiviral.2008.08.008. Epub 2008 Oct 7.
9
Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets.在神经氨酸酶基因中携带R292K突变的流感病毒在雪貂中不会传播。
Antiviral Res. 2002 May;54(2):99-111. doi: 10.1016/s0166-3542(01)00214-5.
10
Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.携带对奥司他韦羧酸盐敏感性降低的神经氨酸酶的流感病毒在体外具有改变的特性，并且在体内的感染性和复制能力受损。
Antiviral Res. 2002 May;54(2):79-88. doi: 10.1016/s0166-3542(01)00215-7.
Zotero 插件